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Abstract: A resveratrol/carboxymethylated glucan (CM-glucan) combination is known to inhibit
rhinovirus replication and expression of inflammatory mediators in nasal epithelia. The aim of
this study was to develop an aerosol formulation containing an association of the two molecules
which could reach the lower respiratory tract. Mass median aerodynamic diameter (MMAD) of
a resveratrol/CM-glucan combination was lower than that shown by resveratrol or CM-glucan
alone (2.83 versus 3.28 and 2.96 µm, respectively). The resveratrol/CM-glucan association results
in the finest and most monodispersed particles in comparison to the two single components. The
association also evidenced lower values for all particle size distribution parameters, suggesting that
the pharmacological synergy observed in previous studies may be accompanied by a pharmaceutical
one. Moreover, we showed that the CM-glucan matrix did not exert an inhibitory effect on
resveratrol nebulization, demonstrating the good suitability of these two molecules in association for
simultaneous aerosol volatilization.
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1. Introduction
Human rhinoviruses (HRV) are the main etiological agents responsible for upper respiratory tract
infections in children and adults. They are the leading cause of the common cold and the exacerbation
of respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). In total,
they are responsible for about 50% of viral respiratory infections and half to two-thirds of cases of
asthma exacerbation induced by viruses [1].
Noteworthy, experimental and observational studies evidenced that HRV can spread to the lower
airway epithelium and act as a lower respiratory tract pathogen [2–6]. Indeed, in-situ hybridization
studies demonstrated that HRV replication occurs in vitro in primary Human Bronchial Epithelial
Cells (HBECs) and in vivo in bronchial tissue of five out of ten subjects experimentally infected [4].
Similar results were obtained by Gern et al. in eight allergic volunteers experimentally infected with
HRV-16 [6]. Rhinovirus RNA was detected by reverse transcription-PCR (RT-PCR) in bronchoalveolar
lavage cells from all subjects two to four days after infection. Furthermore, rhinoviruses induced
release of proinflammatory mediators (interleukin (IL)-6, -8, and -16 and CCL-5 chemokine) from
cultured HBEC (Human Bronchial Epithelial Cells) [4]. Histological analyzes from subjects with
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infections of the lower respiratory tract by HRV have shown that HRV determines both interstitial
and alveolar processes. Indeed, bronchiolitis obliterans with organizing pneumonia [7], interstitial
pneumonitis [8,9], acute and chronic inflammation with fibrinopurulent alveolar debris [10] and
hyperplasia, and desquamation of alveolar cells [11] have been observed. All these studies confirm
that HRV infects the lower airways and induces a proinflammatory response.
We recently showed that resveratrol (Figure 1), a polyphenolic phytoalexin produced by several
plants, inhibits rhinovirus replication and expression of inflammatory mediators in nasal epithelia,
suggesting a potential for application in lower respiratory tract infections, COPD, and asthma [12].
Resveratrol use as a drug has been limited by its poor solubility and scarce bioavailability after oral
administration [13]. Therefore, appropriate preparation and delivery remain issues, though an aerosol
version would have obvious benefits.
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cereals, and bacteria. They are endowed with multiple biological functions and are considered as 
typical “biological response modifiers” as they are able to stimulate the immune system, thus 
exerting anticancer, antiviral, and wound healing effects [13–16]. β-Glucans also increase resistance 
to infections via activation of macrophages/monocytes, neutrophils, and the reticuloendothelial 
system. They stimulate microbial killing and initiate production of innate immune system 
components including inflammatory mediators such as tumor necrosis factor (TNF)-α, IL-1, and 
macrophage inflammatory proteins. β-Glucans are also used in the pharmaceutical industry for their 
drug delivery properties [17]. The carboxymethylation of these biopolymers confers on them 
solubility in an aqueous environment without compromising their biological activities, hence, these 
modified polymers are increasingly being used in pharmaceutical preparations exploiting both their 
pharmaceutical and their biological properties [14]. Our recent work exploring the antiviral capacity 
of the combination of resveratrol and CM-glucan has demonstrated that CM-glucan does not affect 
resveratrol antiviral activity and that the two compounds may act in synergy, exerting 
anti-inflammatory activity by modulating cytokines production [12]. The synergy between β-glucan 
and resveratrol was also demonstrated by previous studies performed by Vetvika et al., who 
demonstrated that this combination stimulates the immune system and that it potentiates the 
anticancer properties compared to the effect exerted by the single substances [18–20]. 
The effectiveness of our new formulation containing the combination of resveratrol/CM-glucan 
was tested as a nasal spray in a clinical trial in asthmatic children and was found to reduce the 
severity and recurrence of upper respiratory tract infections [15,16,21]. Based on this evidence, we 
developed an aerosol formulation for inhalation to reach the bronchial epithelia for the optimal 
anti-inflammatory and antiviral targeted activity. On this topic, a recent paper reported on the 
preparation of resveratrol as a dry powder for inhalation for the treatment of inflammatory lung 
diseases [22]. In this paper, we present evidence that the resveratrol/CM-glucan combination may be 
suitable for the administration via inhalation, suggesting that it could be useful in lower respiratory 
tract infections, COPD, and asthma. 
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CM-glucan and resveratrol alone had MMAD values higher than that of the complex of the two 
molecules (2.83 µm for the complex versus 3.2 and 2.96 µm for resveratrol and CM-glucan, 
respectively). Furthermore, the geometric standard deviation (GSD) is smaller for the complex of the 
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Deviation, is calculated on at least 60,000 particles and is a dimensionless factor that, multiplied and 
divided by the geometric mean of the data set, defines an interval containing 68.27% of the whole 
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single components, as also confirmed by the smaller Span value. 
The resveratrol/CM-glucan sample showed the presence of the finest and also the most 
monodispersed particles in comparison to the two single components that were more heterogeneous 
and polydispersed, as also evidenced from D90, D10, and D50 values, underling that the association 
could be more useful for aerosol applications with respect to the single bioactive molecules. 
Furthermore, only the D90 value for the resveratrol/CM-glucan association is below 5 µm, 
underlying that more than 90% of the product can reach the bronchial alveoli. These features suggest 
that the already demonstrated pharmacological synergy could be accompanied by a pharmaceutical 
one [12–16]. 
Table 1. Particle size distribution of liquid formulations of resveratrol and/or CM-glucan. MMAD = 
mass median aerodynamic diameter; GSD = geometric standard deviation. 
Sample MMAD GSD Mode D90 D10 D50 Span (D90 − D10)/D50 
Resveratrol 3.28 1.488 3.60 5.37 1.89 3.24 1.07 
CM-glucan 2.96 1.506 3.19 5.04 1.70 2.99 1.11 
Resveratrol/CM-glucan 2.83 1.364 2.69 4.65 1.88 2.83 0.97 
Figure 3 shows the chromatographic profile of the CM-glucan aqueous solution overlapped to 
that of the Pullulan molecular weight standards profile (400-200-110 kDa). This analysis revealed 
that the CM-glucan molecular weight is ~250–550 kDa. Notably, this profile did not change during 
the aerosol nebulization process, when CM-glucan was nebulized alone, nor in the presence of 
resveratrol; this also indicates that the different molecular weight species were able to be aerosolized 
with the same efficiency. 
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being used in pharmaceutical preparations exploiting both their pharmaceutical and their biological
properties [14]. Our recent work exploring the antiviral capacity of the combination of resveratrol and
CM-glucan has demonstrated that CM-glucan does not affect resveratrol antiviral activity and that
the two compounds may act in synergy, exerting anti-inflammatory activity by modulating cytokines
production [12]. The synergy between β-glucan and resveratrol was also demonstrated by previous
studies performed by Vetvika et al., who demonstrated that this combination stimulates the immune
system and that it potentiates the anticancer properties compared to the effect exerted by the single
substances [18–20].
The effectiveness of our new formulation containing the combination of resveratrol/CM-glucan
was tested as a nasal spray in a clinical trial in asthmatic children and was found to reduce the
severity and recurrence of upper respiratory tract infections [15,16,21]. Based on this evidence, we
developed an aerosol formulation for inhalation to reach the bronchial epithelia for the optimal
anti-inflammatory and antiviral targeted activity. On this topic, a recent paper reported on the
preparation of resveratrol as a dry powder for inhalation for the treatment of inflammatory lung
diseases [22]. In this paper, we present evidence that the resveratrol/CM-glucan combination may be
suitable for the administration via inhalation, suggesting that it could be useful in lower respiratory
tract infections, COPD, and asthma.
2. Results and Discussion
Our previous work demonstrated that the association of resveratrol with CM-glucan is more
stable in the long term in comparison to aqueous formulations of resveratrol alone [14]. In this paper,
we evaluated the feasibility of an aerosol application of the resveratrol/CM-glucan formulation by
studying some aspects of the nebulization process. First, we analyzed the aerosol MMAD (mass median
aerodynamic diameter) of resveratrol, CM-glucan, and the combination of both compounds in aqueous
liquid formulations. The three samples showed some differences as to the mean diameter, width
of the distribution, and shape of the distribution. Data in Table 1 show that the CM-glucan and
resveratrol alone had MMAD values higher than that of the complex of the two molecules (2.83 µm
for the complex versus 3.2 and 2.96 µm for resveratrol and CM-glucan, respectively). Furthermore,
the geometric standard deviation (GSD) is smaller for the complex of the two molecules compared
with the single components. The GSD, i.e., the Geometric Standard Deviation, is calculated on at least
60,000 particles and is a dimensionless factor that, multiplied and divided by the geometric mean
of the data set, defines an interval containing 68.27% of the whole distribution. This means that the
particle distribution of the complex is narrower than that of the single components, as also confirmed
by the smaller Span value.
Table 1. Particle size distribution of liquid formulations of resveratrol and/or CM-glucan. MMAD =
mass median aerodynamic diameter; GSD = geometric standard deviation.
Sample MMAD GSD Mode D90 D10 D50 Span (D90−D10)/D50
Resveratrol 3.28 1.488 3.60 5.37 1.89 3.24 1.07
CM-glucan 2.96 1.506 3.19 5.04 1.70 2.99 1.11
Resveratrol/CM-glucan 2.83 1.364 2.69 4.65 1.88 2.83 0.97
The resveratrol/CM-glucan sample showed the presence of the finest and also the most
monodispersed particles in comparison to the two single components that were more heterogeneous
and polydispersed, as also evidenced from D90, D10, and D50 values, underling that the association
could be more useful for aerosol applications with respect to the single bioactive molecules.
Furthermore, only the D90 value for the resveratrol/CM-glucan association is below 5 µm, underlying
that more than 90% of the product can reach the bronchial alveoli. These features suggest that
the already demonstrated pharmacological synergy could be accompanied by a pharmaceutical
one [12–16].
Int. J. Mol. Sci. 2017, 18, 967 4 of 11
Figure 3 shows the chromatographic profile of the CM-glucan aqueous solution overlapped to
that of the Pullulan molecular weight standards profile (400–200–110 kDa). This analysis revealed that
the CM-glucan molecular weight is ~250–550 kDa. Notably, this profile did not change during the
aerosol nebulization process, when CM-glucan was nebulized alone, nor in the presence of resveratrol;
this also indicates that the different molecular weight species were able to be aerosolized with the
same efficiency.
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A slight increase in the concentration of the initial material in the chamber was observed within
6 min of nebulization (Figure 4). This slight increase could be due to the faster nebulization of the
solvent in the initial steps of the aerosolizing process. Regarding the residual content of CM-glucan
after complete aerosol nebulization (10 min), data showed that only 3% of the initial material remained
in the nebulizing chamber, indicating that the polymer shows a very good propensity to be sprayed in
a homogeneous manner from a quantitative point of view.
Figure 5 shows resveratrol content in the chamber after different nebulization times. As already
observed for CM-glucan, the polyphenol showed a slight increase in its concentration in the initial
phases of aerosol nebulization, reaching a maximum after 6 min. However, in addition, the residual
content in the aerosol chamber after complete nebulization was low (less than 10% of the initial
amount). After complete aerosolization, we also verified resveratrol presence in nebulized material by
entrapping it in tissue paper filters and by revealing it with Folin–Ciocalteau reagent, confirming the
effective nebulization of the polyphenol (Figure 6). These data indicate that nebulization of resveratrol
was efficient and also that the CM-glucan matrix did not exert an inhibitory effect on its nebulization,
demonstrating the good suitability of these two molecules in association for simultaneous aerosol
volatilization. These features make this association helpful for applications in pharmaceutical aerosols
to be used in virus-induced respiratory diseases such as COPD and asthma.
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formulations in the absence (A) or presence (B) of resveratrol. 
In order to evaluate whether the biological activity of resveratrol was affected by the 
combination with CM-glucan, we tested the effect of resveratrol on HeLa cells, in the presence or 
absence of CM-glucan. It is well known that resveratrol concentrations higher than 30 µM may exert 
an antiproliferative effect on cells. Resveratrol at 100 µM exerted a cytotoxic effect on HeLa cells, 
decreasing cells viability by about 20% after 24 and 48 h incubation. Notably, the association of 
resveratrol with CM-glucan did not alter cell proliferation in a statistically significant manner (Figure 7). 
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In order t evaluate whether the biological activity of r sveratrol was affected by th combination
with CM-glucan, we tested th effect of resveratrol on H La cell , in the presence or abs nce of
CM-glucan. It is well known that resveratrol concentrations higher than 30 µM may exert an
antiproliferative effect on cells. Resveratrol at 100 µM exerted a cytotoxic effect on H La cells,
decreasing cells viability by about 20% after 24 and 48 h incubation. Notably, the association of
resveratrol with CM-glucan did not alter cell proliferation in a statistically significant manner (Figure 7).
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or in the absence of 0.05 mg/mL CM-glucan (CMG). Values are mean ± S.D. and expressed as percent
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3. Materials and Methods
3.1. Reagents
Trans-resveratrol was purchased from Shangai Novanat Co., Ltd. (Shanghai, China) and
CM-glucan from Nutraceutica (Bologna, Italy). HPLC grade solvents used for chromatographic
analyses were purchased from Carlo Erba Reagents (Milan, Italy). All other reagents were analytical
grade products from Sigma-Aldrich (Milan, Italy).
3.2. Samples
Formulation of resveratrol/CM-glucan contained 1 mg/mL of CM-glucan and 0.5 mg/mL of
resveratrol in saline solution. Final resveratrol/CM-glucan ratio was 1:2 (w/w) and the pH of the
formulation was around 5.5–6.0. CM-glucan (0.1% w/v) was dissolved in 0.9% NaCl and magnetically
stirred for 15 min at room temperature. To an aliquot of this solution, resveratrol was added at a
final concentration of 0.05% (w/v). Aqueous solutions of CM-glucan and CM-glucan containing
resveratrol were nebulized by an available commercial aerosol apparatus “MicroLife”. Resveratrol
and CM-glucan quantitative analyses were performed by reverse-phase high performance liquid
chromatography (RP-HPLC) and gel filtration chromatography (GFC), respectively, by sampling the
solutions contained in the nebulizer chamber at 1, 3, and 6 min during aerosolization. After complete
nebulization (about 10 min) the dry residue in the chamber was resuspended in 1 mL of mobile phase
and analyzed by HPLC.
3.3. Particle Size Distribution
Aerosolized samples were fluxed onto the Aerosizer apparatus (Time of Flight Aerosol Beam
Spectrometry “Aerosizer LD”, Amherst Process Instruments Inc., Hadley, MA, USA) at 2 L/min.
We used a run longer than 40 s from a sampling chamber of 13 L where aerosol has been introduced
for about 2 s. Droplets entered into the measuring chamber through a sonic nozzle in which air moves
at about mach2 in a choked flow regime, where gas speed is constant in the supersonic region and
insensitive to pressure fluctuation (pressure fluctuation can change supersonic region length but not
speed inside). As long as the measuring chamber is below 250 mbar, the two laser beams are within
the supersonic region, so drag force applied to particles is known and stable. During the time in which
particles are in the nozzle, they are submitted to a drag force. Time of flight is obtained at the end of the
nozzle by detecting 90 degrees scattering on two parallel HeNe laser beams by two photomultipliers.
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Time of flight aerodynamic mass and then diameter (MMAD) is obtained from Aerosizer software,
based on a calibration curve, factory validated with NIST traceable standards (National Institute of
Standards and Technology). A chamber was used to avoid influence from ambient air and to limit
evaporation. Limited time in aerosol introduction avoided saturation of the chamber and analyzer
overload. Sample stream was generated by a low pressure chamber inside the instrument (at approx.
80 mbar) which sucks air and sample from the sampling chamber [23–25]. To obtain statistically
relevant data, at least 60,000 particles were analyzed for each sample.
3.4. RP-HPLC Resveratrol Analyses
The HPLC consisted of a Waters apparatus equipped with a 600 pump and pump controller,
a Waters autosampler mod. 717, and a UV-Visible Photodiode array detector, mod 2996. For resveratrol
determination, an isocratic chromatographic method was used. Mobile phase was composed by 80% of
solvent A (10% acetic acid) and 20% of solvent B (acetonitrile). The HPLC column was a Symmetry C18
reverse phase (3.9 mm × 150 mm, 5 µm particle size, with a 10 mm guard column of the same material)
and flow rate was 1 mL/min. Resveratrol quantitation was performed by peak area integration at
306 nm. Before the analysis, 20 µL of each sample was diluted 1:10 in mobile phase, filtered onto
0.2 µm filters, and then 50 µL were injected onto the column.
Calibration curve from 75 picomoles to 12 nanomoles was prepared by diluting in appropriate
solvents a 20 mM stock solution of resveratrol in dimethylsulfoxide (DMSO). The curve (six data
points, in duplicate) is linear with an R2 value of 0.999 (Figure 8). Peak detection (retention time: 6 min)
and purity were checked with the photodiode array detector to verify the characteristic absorption
spectrum of the polyphenol (Figure 8, inset).
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3.5. Folin-Ciocalteau Assay
The Folin-Ciocalteau method for qualitative analyses of resveratrol in the nebulized material was
set up by trapping the aerosol nebulized samples on tissue paper filters. The filters were sprayed with
a solution of 30% NaCO3 in water and, after a 3 min incubation, the filter paper was soaked with
Folin–Ciocalteau reagent. After an overnight incubation at room temperature in the absence of light,
a deep blue color developed in the presence of the polyphenol.
3.6. GFC Analyses of CM-Glucan
Chromatographic CM-glucan analysis was performed with a TSK-G3000SW (7.5 mm × 300 mm)
gel filtration column, with the same HPLC apparatus previously described, by using water as the
mobile phase at a flow rate of 0.7 mL/min. For the determination of CM-glucan molecular weight,
a calibration curve was obtained by analyzing 200 µL of a 1 mg/mL mixture of Pullulans analytical
standards (Sigma-Aldrich, Milan, Italy) with different molecular weights. Their retention times
were determined spectrophotometrically by post-column phenol-sulfuric acid derivatization by a
modification of the Mazuko et al method [26]. Briefly, fractions of 0.5 mL were collected and aliquots
of 50 µL were added to 150 µL of concentrated sulfuric acid (95%) in a polypropylene 1.5 mL tube.
Subsequently, 30 µL of 5% phenol in water were added. After incubating at 90 ◦C for 5 min, the
vials were cooled to room temperature in a water bath and 100 µL was transferred to a 96-well
microplate. The optical density of each well was determined at 490 nm with a reference at 690 nm
using a microplate reader (Appliskan microplate reader, Thermo Scientific, Vantaa, Finland).
CM-glucan detection was performed with a photodiode array detector (PDA) by monitoring
the UV absorbance of -COOH moiety at 220 nm. For CM-glucan quantitative analysis, a calibration
curve (Figure 9) in the range 0.1–1 mg was prepared by replicate injections of CM-glucan at different
concentrations (R2 = 0.99).
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containing gentamicin and 4 mM glutamine. Cell viability, in the presence or absence of resveratrol
or resveratrol/CM-glucan, was determined by using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl
tetrazolium bromide (MTT) dye reduction assay. Briefly, cells were seeded in 96-well plates at a
concentration of 19,000 cells per well in order to obtain cells in sub-confluent conditions after 48 h.
Cells were treated with different concentrations of resveratrol or resveratrol/CM-glucan maintaining
the molar ratio used for all other experiments (1:2 w/w) and incubated at 37 ◦C in 5% CO2 atmosphere
for 24 h. After treatment, 20 µL of a 5 mg/mL solution of MTT in PBS was added per well, and cells
were incubated at 37 ◦C for 2 h. The supernatants were then removed and formazan crystals were
dissolved in 100 µL of DMSO. The absorbance of each solution was determined at 570 nm with a
reference at 690 nm using a microplate reader.
4. Conclusions
Glucans are an extremely interesting group of biopolymers endowed with many different
pharmaceutical and pharmacological properties. Their use in pharmaceutical preparations and in the
food industry is steadily increasing.
During the last years, our group has been studying the pharmaceutical and pharmacological
properties of resveratrol and evaluated possible synergies with other bioactive molecules, in particular
with carboxymethylated β-glucan. This association was found to be effective in preventing resveratrol
degradation in water and in counteracting rhinovirus infection in human nasal epithelia by altering
virus replication and the expression of inflammatory mediators in nasal epithelia. Its use as a nasal
spray in upper respiratory tract infections was demonstrated to be safe and effective [14–16]. The
positive interaction between β-glucan and resveratrol is also supported by a number of studies showing
a significant synergy of the two compounds in stimulating the immune system [18] and in strongly
reducing stress-related symptoms, including corticosterone levels and IL-6, IL-12, and interferon
(IFN)-γ production compared to that of its individual components [27].
Inhaled aerosol therapies are the mainstay of treatment of lower respiratory tract diseases such
as viral infections, allowing for high local drug concentrations. The aim of the present work was
to develop an aerosol formulation containing an association of resveratrol and CM-glucan which
could reach the lower respiratory tract. Our data demonstrate that it is possible to develop an aerosol
product containing s a stabilized form of resveratrol. The particle size (expressed as MMAD) is
of critical importance as the drug delivery depends on this to a major extent. We demonstrated
that resveratrol/CM-glucan association results in the finest and most monodispersed particles when
compared with the two single components. The association also evidenced lower values for all particle
size distribution parameters suggesting that the pharmacological synergy, observed in previous studies,
may be accompanied by a pharmaceutical one. Moreover, we showed that the CM-glucan matrix
did not exert an inhibitory effect on resveratrol nebulization, demonstrating the good suitability of
these two molecules in association for simultaneous aerosol volatilization. All these features make the
resveratrol/CM-glucan association helpful for aerosol treatment of patients requiring antiviral and/or
anti-inflammatory medication for lower respiratory tract diseases.
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Abbreviations
RP-HPLC reversed phase high pressure liquid chromatography
GFC gel filtration chromatography
MMAD mass median aerodynamic diameter
GSD geometric standard deviation
HBEC Human Bronchial Epithelial Cells
MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
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